Abstract:OBJECTIVE:To investigate the characteristics of airway inflammation in severe asthma and the association with interleukin-17 (IL-17). METHODS:Sixteen patients with mild persistent asthma, 14 patients with moderate persistent asthma and 18 patients with severe persistent asthma, as well as 15 normal control subjects, were included in this study. At baseline, asthma symptom score was recorded, and lung function was measured. Induced sputum was obtained and processed for cell differential and the supernatant was assayed for the concentrations of IL-17 and IL-8 by sandwich enzyme-linked immunosorbent assay (ELISA), eosinophil cationic protein (ECP) by the immuno-CAP system, and neutrophil myeloperoxidase (MPO) by a colorimetric method, and the values were normalized to the protein content. Then 15 mild to moderate and 15 severe asthmatic patients received inhaled corticosteroid (Pulmicort, Astra-Zeneca) therapy for 4 weeks, and the above measurements were repeated. RESULTS:The percentage of sputum eosinophils and the level of ECP were significantly increased in mild [0.0670 +/- 0.0740, (155 +/- 91) x 10(-6) g/g protein], moderate [0.0830 +/- 0.0440, (180 +/- 83) x 10(-6) g/g protein] and severe [0.1240 +/- 0.1430, (191 +/- 87) x 10(-6) g/g protein] asthmatic patients, as compared to the normal controls [0.0000 +/- 0.0010, (44 +/- 25) x 10(-6) g/g protein, P < 0.01)]; but there was no significant difference among mild, moderate and severe asthma (P > 0.05). On the contrary, the percentage of sputum neutrophils was significantly increased in patients with severe asthma (0.589 +/- 0.203) as compared to patients with mild (0.455 +/- 0.154) and moderate (0.449 +/- 0.194) asthma and normal controls (0.313 +/- 0.134, P < 0.01). The level of MPO was also increased in severe asthma [(31 +/- 10 ) U/g protein] as compared to mild [(12 +/- 4) U/g protein] and moderate [(22 +/- 7) U/g protein] asthma and normal controls [(10 +/- 4) U/g protein, P < 0.01]. The sputum level of IL-17 in severe, moderate asthma [(264 +/- 137) x 10(-9) g/g protein, (172 +/- 65) x 10(-9) g/g protein] was significantly higher than those in mild asthma [(126 +/- 52) x 10(-9) g/g protein] and normal controls [(56 +/- 20) x 10(-9) g/g protein, P < 0.01]. As compared to the normal controls [(83 +/- 36) x 10(-9) g/g protein], the level of IL-8 in severe asthma [(531 +/- 321) x 10(-9) g/g protein] was significantly increased (P < 0.01), and those in mild [(410 +/- 181) x 10(-9) g/g protein] and moderate [(438 +/- 148) x 10(-9) g/g protein] asthma were also increased, although the difference was not statistically significant (P > 0.05). The level of IL-17 was correlated positively with IL-8, neutrophils and MPO (r = 0.525, 0.349, 0.602, all P < 0.01). After steroid therapy, the percentage of eosinophils, the levels of ECP, MPO, IL-17 and IL-8 decreased significantly in all patients combined, but the percentage of neutrophils remained unchanged (P > 0.05) and still significantly higher in severe asthmatic patients (0.642 +/- 0.157) as compared to mild and moderate asthmatic patients (0.394 +/- 0.147, P < 0.01). CONCLUSIONS:Airway neutrophilia is a feature of severe asthma. The IL-17/IL-8 pathway may be involved in the initial neutrophil influx into the airways.

Exploration of plasma interleukin-27 levels in asthma patients and the correlation with lung function

[Determination of Th1/Th2 Cytokines and Chemokines in Patients with Allergic Diseases and Its Significance].

Interleukin-31 Expression and Relation to Disease Severity in Human Asthma.

The IL6R Gene Polymorphisms Are Associated with Sil-6R, IgE and Lung Function in Chinese Patients with Asthma.

The levels of interleukin 17 in induced sputum in patients with severe asthma and its relationship to airway inflammation and airflow limitation

Preventative Tracheal Administration of Interleukin-27 Attenuates Allergic Asthma by Improving the Lung Th1 Microenvironment

STAT3 and IL-6 Contribute to Corticosteroid Resistance in an OVA and Ozone-induced Asthma Model with Neutrophil Infiltration

Correlation of treatment compliance analysis with lung function and control level in asthma

An observation of plasma of interleukin-5 and interleukin-10 concentrations in asthmatic patients

Enhanced Local Foxp3 Expression in Lung Tissue Attenuates Airway Inflammation in A Mouse Model of Asthma

[The Levels and Clinical Implications of Induced Sputum Interleukin-17 in Chronic Obstructive Pulmonary Disease and Asthma].

[Characteristics of the Airway Inflammation and the Relationship to Interleukin-17 in Severe Asthma].

The roles of thymic stromal lymphopoietin receptor and its antibody in airway inflammatory response in asthmatic mice

Different expression levels of interleukin-36 in asthma phenotypes

IL-27 Attenuates Airway Inflammation in a Mouse Asthma Model Via the STAT1 and GADD45γ/p38 MAPK Pathways

IL-13+ Type 2 Innate Lymphoid Cells Correlate with Asthma Control Status and Treatment Response.

Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations

Interleukin-36 Receptor Antagonist Alleviates Airway Inflammation in Asthma Via Inhibiting the Activation of Interleukin-36 Pathway.

Detection and Significance of Serum Th17 Cell Related Cytokines in Patients with Bronchial Asthma

Clinical Significance of Combined Detection of CCL22 and IL‐1 as Potential New Bronchial Inflammatory Mediators in Children's Asthma

IL-33 amplifies airways inflammation in a murine surrogate of asthma possibly through acting on dendritic cells